Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors

NCT03095248 is registered in ClinicalTrials.gov with Children's Hospital Medical Center, Cincinnati as lead sponsor.

NCT NCT03095248
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03095248 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Phase
Phase 2
Overall status
Terminated
Start date
May 8, 2017
Completion date
May 21, 2024
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ependymoma, glioma, meningioma, neurofibromatosis 2, vestibular schwannoma